PATENT CLAIM ANALYSIS

Application Number: 15966103
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["424", "093710"]

Abstract:
The invention is directed to modified T cells, methods of making and using isolated, modified T cells, and methods of using these isolated, modified T cells to address diseases and disorders. In one embodiment, this invention broadly relates to TCR-deficient T cells, isolated populations thereof, and compositions comprising the same. In another embodiment of the invention, these TCR-deficient T cells are designed to express a functional non-TCR receptor. The invention also pertains to methods of making said TCR-deficient T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said TCR-deficient T cells, populations thereof, or compositions comprising the same.

Claim (Index 49):
The method of  claim 38 , wherein the signaling domain is obtained from CD3\u03b6.

Metadata:
- Claim Count in Document: 29.0
- Percentile: 91.0
- Lexical Diversity: 2.4898
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13459664', '14934256', '13502978', '15003968', '15948303']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7523019895370225
- 35 USC 102 Novelty (BERT): 0.5780624958894518
- Combined Prediction Score: 0.7348780401722655
- Mean Citation Score: 519.2540019999999
- Max Citation Score: 542.2982
- Similarity Product: 346.4142854815244

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test